Astellas Pharma to Transfer Manufacturing Plant, Business to Delpharm
This agreement is intended to be executed and see the impact of any financial transfers by the fiscal year ending March 31, 2024.
Astellas Pharma announced on May 25, 2023 that Astellas B.V., Astellas Pharma Europe B.V., and Astellas’ subsidiaries in the Netherlands have decided to sell and transfer the manufacturing plant located in Meppel to Delpharm Industries. This agreement is intended to be executed and see the impact of any financial transfers by the fiscal year ending March 31, 2024.
Astellas hopes to continue to strengthen its capabilities in the technology and manufacturing sector, and it hopes to partner with Delpharm for promoting a more stable supply of high-quality medicines, according to the company press release. Under the agreement, Delpharm will continue to manufacture the products that are currently manufactured at the Meppel plant, with these products being delivered to the Astellas group. Further, employees from Astellas will also transfer to Delpharm.
Source: Astellas
WMFTS’ BioPure to Showcase Single-Use Bioclamp with Refined Manufacturing at INTERPHEX 2025
April 1st 2025With advanced manufacturing, BioPure’s BioClamp connector is manufactured to be 13% lighter than the previous model, resulting in a 26% reduction in carbon dioxide emissions across the full lifecycle of the product.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
